Bristol-Myers Squibb (BMY) – Hot Comments
-
Redburn-Atlantic Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral, 'With limited near-term material pipeline updates'
-
Fusion Pharmaceuticals (FUSN) is 'sole remaining clinical-stage, targeted radiopharm player,' seen as takeover target - Oppenheimer
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BMY Stock Lookup